The activity of nivolumab in subgroups of patients with tumors which have wild-type Importance BRAF kinase vs patients with tumors having mutant BRAF has not systematically been explored in a large dataset.

READ FULL ARTICLE Curated publisher From oncology.jamanetwork.com